AU746930B2 - Therapeutic compositions - Google Patents
Therapeutic compositions Download PDFInfo
- Publication number
- AU746930B2 AU746930B2 AU23803/99A AU2380399A AU746930B2 AU 746930 B2 AU746930 B2 AU 746930B2 AU 23803/99 A AU23803/99 A AU 23803/99A AU 2380399 A AU2380399 A AU 2380399A AU 746930 B2 AU746930 B2 AU 746930B2
- Authority
- AU
- Australia
- Prior art keywords
- therapeutic composition
- composition according
- diosgenin
- dry
- equiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Regulation 3.2
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
o
C.
Name of Applicant: STOLAIR PTY LTD Actual Inventor: Warwick Deane Raymont Address for Service: MADDERNS, 1st Floor, 64 Hindmarsh Square,
*.C
Invention title: THERAPEUTIC COMPOSITIONS
S
Details of Associated Provisional Application No: PP 3188 dated 24th April 1998 The following statement is a full description of this invention, including the best method of performing it known to us.
BACKGROUND TO THE INVENTION Many health food supplements which are currently being marketed rely for their effectiveness on the combined effects of the various components.
It has now surprisingly been found that a particular combination of active ingredients has a significant synergistic effect, with the therapeutic effect of the composition being considerably greater than the additive effects of the various components.
DESCRIPTION OF THE INVENTION The therapeutic compositions of the present invention comprise a synergistic mixture of linoleic acid and/or linolenic acid and diosgenin, and a pharmaceutically S* acceptable carrier vehicle, optionally together with other active ingredients. The synergistic effect may be enhanced by additionally incorporating Trillium erectum S 15 (Beth Root) or an extract thereof.
The linoleic/linolenic acid component is conveniently provided by linseed oil, which comprises glycerides of linoleic, linolenic, oleic, stearic, palmitic and myristic acids.
Diosgenin is a saponin which may be obtained, for example, from the roots of the wild yam (Dioscorea villosa), or from other plant sources, such as other species of Dioscorea. Diosgenin can be converted in vivo to DHEA (ie. dehydroepiandrosterone or 3-hydroxyandrost-5-en-17-one). The DHEA produced in the patient's body has a beneficial effect on the immune system, and also assists in relieving stress or PMT (pre-menstrual tension), by helping to balance the body's hormones through natural conversion of the DHEA to (for example) progesterone.
It has surprisingly been found that the conversion rate of diosgenin into DHEA is enhanced by the linoleic/linolenic acid content of linseed oil. There is up to a hundredfold increase in the conversion rate of the diosgenin, when facilitated by linoleic acid/linolenic acid, in the presence of Trillium erectum. It is believed that Trillium erectum facilitates removal of a bulky functional group from, and *C modification of, the fifth cyclic ring of diosgenin. That bulky functional group would otherwise be an impediment in conversion of diosgenin to DHEA.
Linoleic acid and linolenic acid are essential fatty acids, and accordingly have the added advantage of forming nutrient components of the therapeutic compositions of the present invention.
Preferably, the therapeutic compositions of the present invention comprise 0.5 w/w of linseed oil, and 0.1 0.5% w/w of diosgenin. The ratio of linseed oil to diosgenin in the compositions is preferably from 1:1 to 4:1 (by weight).
The invention will now be further described with respect to the following Example, which is illustrative but not restrictive of the present invention.
EXAMPLE
The following formulation is compounded into tablets: ACTIVE INGREDIENTS PER TABLET Cimicifuga racemosa (Black cohosh) root ext. dry conc. (4:1 in W) 40 mg (equiv. Cimicifuga racemosa root dry 160mg) Trillium erectum (Beth Root) 50 mg root ext. dry conc. (4:1 in 60% E:W) (equiv. Trillium erectum root dry 200mg) Vitex agnus-castus (Chaste Tree) fruit ext. dry cone. (10:1 in 50% E:W) 10 mg (equiv. Vitex agnus-castus fruit dry 100mg Centaurium erythraea (Centaury) 25 mg herb ext. dry conc. (4:1 in 30% E:W) (equiv. Centaurium erythraea herb dry 100mg) Taraxacum officinale (Dandelion) whole plant ext. dry cone. (4.5:1 in W) 23.11 mg (equiv. Taraxacum officinale whole plant dry 104mg) Echinacea purpurea (Echinacea) root ext. dry conc. (6:1 in 30% E:W) 40 mg (equiv. Echinacea purpurea root dry 240mg) Crataegus monogyna (Hawthorn) herb ext. dry cone. (4:1 in 30% Methanol:W) 40 mg (equiv. Crataegus monogyna herb dry 160mg)_ r Linseed Oil (equiv. Oleic Acid 1.75mg) (equiv. Linoleic Acid 1.75mg) 10 mg (equiv. Linolenic Acid 5.75mg) Petroselinum crispum (Parsley) seed ext. dry cone. (4:1 in 50% E:W) 30 mg (equiv. Petroselinum crispum seed dry 120mg) Trifolium pratense (Red Clover) flower ext. dry cone. (4:1 in 15% E:W) 30 mg (equiv. Trifolium pratense flower dry 120mg) Viola odorata (Violet Leaves) Herb ext. dry conc. (4:1 in 60% E:W) 15 mg (equiv. Viola odorata dry Dioscorea villosa (Wild Yam) root ext. dry conc. (10:1 in 90% E:W) stand. 75 mg (equiv Dioscorea villosa root dry 750mg) (equiv. Saponins 4.5mg calculated as Diosgenin) Customary excipients may be included, as desired.
While the present invention has been described in terms of a preferred embodiment in order to facilitate better understanding of the invention, it should be appreciated that various modifications can be made without departing from the principles of the invention. Therefore, the invention should be understood to include all such modifications within its scope.
Claims (8)
1. A therapeutic composition comprising a synergistic mixture of: linoleic acid and/or linolenic acid and diosgenin, and a pharmaceutically acceptable carrier vehicle.
2. A therapeutic composition according to claim 1, wherein component is provided in the form of linseed oil.
3. A therapeutic composition according to claim 2, comprising 0.5-1.0% w/w of linseed oil.
4. A therapeutic composition according to claim 2 or claim 3, wherein the ratio of linseed oil to diosgenin is from 1:1 to 4:1 (by weight).
5. A therapeutic composition according to any one of claims 1 to 4, comprising 0.1-0.5% w/w of diosgenin.
6. A therapeutic composition according to any one of claims 1 to 5, wherein the diosgenin is derived from the roots of the wild yam (Dioscorea villosa).
7. A therapeutic composition according to any one of claims 1 to 6, further comprising Trillium erectum (Beth Root) or an extract thereof.
8. A therapeutic composition according to any one of claims 1 to 7, substantially as described herein and with reference to the Example. Dated this 16th day of April 1999. STOLAIR PTY LTD By its Patent Attorneys (;//WdA
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU23803/99A AU746930B2 (en) | 1998-04-24 | 1999-04-16 | Therapeutic compositions |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP3188A AUPP318898A0 (en) | 1998-04-24 | 1998-04-24 | Therapeutic compositions |
| AUPP3188 | 1998-04-24 | ||
| AU23803/99A AU746930B2 (en) | 1998-04-24 | 1999-04-16 | Therapeutic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2380399A AU2380399A (en) | 1999-11-04 |
| AU746930B2 true AU746930B2 (en) | 2002-05-09 |
Family
ID=25619137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23803/99A Ceased AU746930B2 (en) | 1998-04-24 | 1999-04-16 | Therapeutic compositions |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU746930B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6165323B2 (en) * | 2014-04-25 | 2017-07-19 | レジリオ株式会社 | A therapeutic agent for diseases involving neuronal axon dysfunction, including a therapeutic agent for Alzheimer's disease |
-
1999
- 1999-04-16 AU AU23803/99A patent/AU746930B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2380399A (en) | 1999-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4987150A (en) | Agent for inhibiting binding of 5-dihydro-testosterone with androgen receptor as well as process for obtaining same | |
| Afolayan et al. | Phytochemical analysis and in vitro antioxidant activity of Nymphaea lotus L | |
| JP2005255527A (en) | Composition for in vivo collagen synthesis promotor | |
| Mala et al. | Therapeutic efficacy of Centella asiatica (L.) and Momordica charantia: As traditional medicinal plant | |
| RU2009126461A (en) | HERBAL COMPOSITION FOR HEALING OF RAS | |
| Béjar et al. | Pharmacological and chemical screening of Byrsonima crassifolia, a medicinal tree from Mexico. Part I | |
| AU754161B2 (en) | Extracts of (hypericum perforatum) and formulations containing them | |
| Pal et al. | Antioxidant, anti-alzheimer and anti-parkinson activity of Artemisia nilagirica leaves with flowering tops | |
| Barve et al. | Extraction of saponins from Safed Musli | |
| NO328245B1 (en) | Extracts of Tanacetum parthenium and pharmaceutical and cosmetic compositions containing the extracts. | |
| Daneshrad et al. | Chemical studies of the oil from pistacia nuts growing wild in Iran | |
| AU746930B2 (en) | Therapeutic compositions | |
| JP6385218B2 (en) | A composition comprising a saw palm fruit extract and a button bud extract | |
| JPS5758613A (en) | Composition for oral cavity application | |
| Bourdy et al. | Maternity and medicinal plants in Vanuatu II. Pharmacological screening of five selected species | |
| Longo et al. | Constituents of Pygeum africanum bark | |
| Kumar et al. | Evaluation of antioxidant potential of alcoholic stem bark extracts of Bauhinia variegata Linn. | |
| JPS6236330A (en) | Swertia japonica herba extract and production thereof | |
| Matamane et al. | DPPH radical scavenging activity of extracts from Buddleja salviifolia | |
| US20010036485A1 (en) | Herbal composition and method for promoting emotional well-being | |
| FR2659556A1 (en) | Compositions based on arnica and their uses, in particular in pharmaceutical or cosmetic compositions | |
| JP2004137227A (en) | Aerosol cosmetic | |
| Zafra‐Polo et al. | Antiinflammatory activity of sesquiterpene lactones from Artemisia barrelieri in rats | |
| Erdogan et al. | Fatty acid compositions and anti-inflammatory activities of Tripleurospermum parviflorum (Willd.) Pobed. and Tripleurospermum tenuifolium (Kit.) | |
| Abdulameer et al. | Effect of palm pollen and pomegranate peel supplementation on sperm development in male rabbits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NEW CHAPTER IP PTY LTD Free format text: FORMER OWNER WAS: STOLAIR PTY LTD |